Progenra, Inc.

Dedicated to finding new medicines for a variety of diseases by targeting the ubiquitin pathway, a critical mechanism of cellular regulation. Using our UbiPro™ Discovery Platform we have identified selective inhibitors of critical ubiquitin pathway enzymes associated with cardiovascular disease, cancer and other debilitating diseases. This technology and multiple selective compounds are available for licensing. 

Novel Science

Progenra’s goal is to discover novel drugs targeting the ubiquitin pathway using their proprietary technology.

DEUBIQUITYLASE TECHNOLOGIES

Download [pdf]

E3 LIGASE TECHNOLOGY

Download [pdf]

Business Development

Progenra is seeking industry partnerships for licensing opportunities surrounding the company’s small molecule portfolio and/or its proprietary UbiPro™ Drug Discovery Platform.




Progenra Headlines

Date: 11.12.14

Progenra Chairs Ubiquitin Symposium at the Society for Neuroscience Conference, November 15-19, Washington, DC

Progenra is chairing a Ubiquitin Symposium on “The Latest on Ubiquitin Pathway and Neurodegeneration Disease” This symposium brings together leaders in ubiquitin pathway research applied to translational medicine and drug discovery in neuroscience.

Read More »